Merck KGaA (FRA:MRK) has been assigned a €115.00 ($133.72) target price by analysts at Sanford C. Bernstein in a research report issued to clients and investors on Wednesday. The brokerage currently has a “buy” rating on the healthcare company’s stock. Sanford C. Bernstein’s price objective indicates a potential upside of 28.12% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. set a €94.00 ($109.30) target price on Merck KGaA and gave the stock a “neutral” rating in a report on Wednesday, August 9th. Independent Research GmbH set a €105.00 ($122.09) price objective on Merck KGaA and gave the company a “neutral” rating in a research note on Wednesday, September 6th. Kepler Capital Markets set a €115.00 ($133.72) price objective on Merck KGaA and gave the company a “buy” rating in a research note on Wednesday, October 4th. J P Morgan Chase & Co set a €100.00 ($116.28) price objective on Merck KGaA and gave the company a “neutral” rating in a research note on Friday, October 6th. Finally, Berenberg Bank set a €116.00 ($134.88) price objective on Merck KGaA and gave the company a “buy” rating in a research note on Tuesday, September 19th. Twelve analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of €108.87 ($126.59).

Merck KGaA (MRK) traded down €1.02 ($1.19) during trading on Wednesday, hitting €89.76 ($104.37). The company’s stock had a trading volume of 556,069 shares. Merck KGaA has a 52-week low of €89.21 ($103.73) and a 52-week high of €115.00 ($133.72).

ILLEGAL ACTIVITY NOTICE: “Merck KGaA (MRK) Given a €115.00 Price Target at Sanford C. Bernstein” was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/15/merck-kgaa-mrk-given-a-115-00-price-target-at-sanford-c-bernstein.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.